Brukinsa
Is Now Approved

FOR ADULT PATIENTS WITH MANTLE CELL
LYMPHOMA (MCL) WHO HAVE RECEIVED
AT LEAST ONE PRIOR THERAPY

BRUKINSA (zanubrutinib) is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.